These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
214 related articles for article (PubMed ID: 34507552)
1. Adjuvant immunotherapy recommendations for stage III melanoma: physician and nurse interviews. Livingstone A; Dempsey K; Stockler MR; Howard K; Long GV; Carlino MS; Menzies AM; Morton RL BMC Cancer; 2021 Sep; 21(1):1014. PubMed ID: 34507552 [TBL] [Abstract][Full Text] [Related]
2. Should I Have Adjuvant Immunotherapy? An Interview Study Among Adults with Resected Stage 3 Melanoma and Their Partners. Livingstone A; Milne D; Dempsey K; Muscat DM; Menzies AM; Howard K; Stockler MR; Morton RL Patient; 2021 Sep; 14(5):635-647. PubMed ID: 33759137 [TBL] [Abstract][Full Text] [Related]
3. Preferences for Adjuvant Immunotherapy in Adults with Resected Stage III Melanoma-A Discrete Choice Experiment. Livingstone A; Howard K; Menzies AM; Long GV; Stockler MR; Morton RL Patient; 2023 Sep; 16(5):497-513. PubMed ID: 37351797 [TBL] [Abstract][Full Text] [Related]
4. Balancing the Hype with Reality: What Do Patients with Advanced Melanoma Consider When Making the Decision to Have Immunotherapy? Wong A; Billett A; Milne D Oncologist; 2019 Nov; 24(11):e1190-e1196. PubMed ID: 31015314 [TBL] [Abstract][Full Text] [Related]
5. Adjuvant immunotherapy with tumor infiltrating lymphocytes and interleukin-2 in patients with resected stage III and IV melanoma. Ridolfi L; Ridolfi R; Riccobon A; De Paola F; Petrini M; Stefanelli M; Flamini E; Ravaioli A; Verdecchia GM; Trevisan G; Amadori D J Immunother; 2003; 26(2):156-62. PubMed ID: 12616107 [TBL] [Abstract][Full Text] [Related]
6. Management options for metastatic melanoma in the era of novel therapies: a primer for the practicing dermatologist: part I: Management of stage III disease. Fox MC; Lao CD; Schwartz JL; Frohm ML; Bichakjian CK; Johnson TM J Am Acad Dermatol; 2013 Jan; 68(1):1.e1-9; quiz 10-12. PubMed ID: 23244383 [TBL] [Abstract][Full Text] [Related]
7. The role of adjuvant therapy in melanoma management. Barth A; Morton DL Cancer; 1995 Jan; 75(2 Suppl):726-34. PubMed ID: 7805001 [TBL] [Abstract][Full Text] [Related]
8. Shared care in the follow-up of early-stage melanoma: a qualitative study of Australian melanoma clinicians' perspectives and models of care. Rychetnik L; Morton RL; McCaffery K; Thompson JF; Menzies SW; Irwig L BMC Health Serv Res; 2012 Dec; 12():468. PubMed ID: 23253951 [TBL] [Abstract][Full Text] [Related]
9. Comorbidity burden on receipt of adjuvant immunotherapy and survival in patients with stage III melanoma: an analysis of the National Cancer Database. Freeman SC; Satish M; Walters RW Int J Dermatol; 2020 Nov; 59(11):1381-1390. PubMed ID: 32592609 [TBL] [Abstract][Full Text] [Related]
10. From decision to reflection: understanding the experiences and unmet care needs of patients treated with immunotherapy for melanoma in the adjuvant or metastatic setting. Kamminga NCW; van der Veldt AAM; Wakkee M; van den Berge FR; van der Beek LAA; Joosen MCW; Joosse A; de Joode K; Nijsten TEC; Lugtenberg M BMC Cancer; 2024 May; 24(1):662. PubMed ID: 38816701 [TBL] [Abstract][Full Text] [Related]
11. Variation in the depth of excision of melanoma: A survey of US physicians. DeFazio JL; Marghoob AA; Pan Y; Dusza SW; Khokhar A; Halpern A Arch Dermatol; 2010 Sep; 146(9):995-9. PubMed ID: 20644028 [TBL] [Abstract][Full Text] [Related]
12. Deciding on adjuvant chemotherapy for elderly patients with stage III colon cancer: a qualitative insight into the perspectives of surgeons and medical oncologists. van Erning FN; Janssen-Heijnen ML; Creemers GJ; Pruijt HF; Maas HA; Lemmens VE J Geriatr Oncol; 2015 May; 6(3):219-24. PubMed ID: 25703856 [TBL] [Abstract][Full Text] [Related]
13. Contemporary management of locoregionally advanced melanoma in Australia and New Zealand and the role of adjuvant systemic therapy. Smithers BM; Saw RPM; Gyorki DE; Martin RCW; Atkinson V; Haydon A; Roberts-Thomson R; Thompson JF ANZ J Surg; 2021 Aug; 91 Suppl 2():3-13. PubMed ID: 34288329 [TBL] [Abstract][Full Text] [Related]
14. [Adjuvant adoptive immunotherapy in patients with stage III and resected stage IV melanoma: a pilot study]. Verdecchia GM; Ridolfi L; Ridolfi R; Riccobon A; Bertagni A; Vagliasindi A; Petrini M; Stefanelli M; Milandri C; Amadori D Tumori; 2003; 89(4 Suppl):298-300. PubMed ID: 12903626 [TBL] [Abstract][Full Text] [Related]
15. Adjuvant NY-ESO-1 vaccine immunotherapy in high-risk resected melanoma: a retrospective cohort analysis. Lattanzi M; Han J; Moran U; Utter K; Tchack J; Sabado RL; Berman R; Shapiro R; Huang HH; Osman I; Bhardwaj N; Pavlick AC J Immunother Cancer; 2018 May; 6(1):38. PubMed ID: 29773080 [TBL] [Abstract][Full Text] [Related]
16. Decision-making under clinical uncertainty: An in-depth examination of provider perspectives on adjuvant chemotherapy for stage II colon cancer. Shelton RC; Brotzman LE; Crookes DM; Robles P; Neugut AI Patient Educ Couns; 2019 Feb; 102(2):284-290. PubMed ID: 30262401 [TBL] [Abstract][Full Text] [Related]
17. Developing indications for the use of sentinel lymph node biopsy and adjuvant high-dose interferon alfa-2b in melanoma. Dubois RW; Swetter SM; Atkins M; McMasters K; Halbert R; Miller SJ; Shiell R; Kirkwood J Arch Dermatol; 2001 Sep; 137(9):1217-24. PubMed ID: 11559220 [TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial. Amaria RN; Prieto PA; Tetzlaff MT; Reuben A; Andrews MC; Ross MI; Glitza IC; Cormier J; Hwu WJ; Tawbi HA; Patel SP; Lee JE; Gershenwald JE; Spencer CN; Gopalakrishnan V; Bassett R; Simpson L; Mouton R; Hudgens CW; Zhao L; Zhu H; Cooper ZA; Wani K; Lazar A; Hwu P; Diab A; Wong MK; McQuade JL; Royal R; Lucci A; Burton EM; Reddy S; Sharma P; Allison J; Futreal PA; Woodman SE; Davies MA; Wargo JA Lancet Oncol; 2018 Feb; 19(2):181-193. PubMed ID: 29361468 [TBL] [Abstract][Full Text] [Related]
19. Variations in management of stage I to stage III cutaneous melanoma: a population-based study of clinical practices in France. Grange F; Vitry F; Granel-Brocard F; Lipsker D; Aubin F; Hédelin G; Dalac S; Truchetet F; Michel C; Batard ML; Baury B; Halna JM; Schmutz JL; Delvincourt C; Reuter G; Dalle S; Bernard P; Danzon A Arch Dermatol; 2008 May; 144(5):629-36. PubMed ID: 18490589 [TBL] [Abstract][Full Text] [Related]